Deals
Samsung Biologics, Bobcat Brave Asia’s 2nd-Worst IPO Market
- South Korean listings this year set to reach most since 2010
- Stable Kospi, earnings to lure investors, arranger says
This article is for subscribers only.
South Korea’s initial public offerings are the second-worst performers among major Asian markets this year. That hasn’t stopped companies from planning more new listings, which are poised to raise the most since 2010.
Following nine listings this year, at least 10 more firms, including Doosan Bobcat Inc. and Samsung Biologics Co., have lined up share sales. As policy makers ease rules, the total issuance this year is likely to be the biggest since 22 companies raised 8.7 trillion won ($7.7 billion) in 2010, Lee Seong Gil, head of listing promotions at Korea Exchange, the nation’s largest, said in an interview.